Journal article · 2023 · Open access
P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?
Value in Health, 26(6), S9 · Published 1 June 2023 · DOI 10.1016/j.jval.2023.03.052
In brief
“P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” is a 2023 journal article by D. Patil and E Oehrlein, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access: the full text is free to read at Value in Health.
- Citations
- 0
- Authors
- 2
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Patil, D., & Oehrlein, E. (2023). P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022? Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.052
MLA 9
Patil, D., and E Oehrlein. “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” Value in Health, vol. 26, no. 6, 2023, p. S9. https://doi.org/10.1016/j.jval.2023.03.052.
Chicago
Patil, D. and E Oehrlein. 2023. “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” Value in Health 26 (6): S9. https://doi.org/10.1016/j.jval.2023.03.052.
Harvard
Patil, D. and Oehrlein, E. (2023) ‘P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?’, Value in Health, 26(6), p. S9. doi:10.1016/j.jval.2023.03.052.
IEEE
D. Patil and E. Oehrlein, “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?,” Value in Health, vol. 26, no. 6, p. S9, 2023, doi: 10.1016/j.jval.2023.03.052.
BibTeX
@article{patil2023consider,
title = {{P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?}},
author = {Patil, D. and Oehrlein, E},
journal = {Value in Health},
year = {2023},
volume = {26},
number = {6},
pages = {S9},
doi = {10.1016/j.jval.2023.03.052},
url = {https://doi.org/10.1016/j.jval.2023.03.052}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- patient experience data
- FDA regulatory decision
- drug approval
- patient-reported outcomes
- regulatory decision-making
- drug approval trends
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Patil, D., & Oehrlein, E. (2023). P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022? Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.052
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Value in Health: sign in and open the PDF from this page.
Who wrote this paper?
D. Patil, E Oehrlein.
What is the DOI of this paper?
10.1016/j.jval.2023.03.052, permanently at https://doi.org/10.1016/j.jval.2023.03.052. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.